论文部分内容阅读
目的研究非小细胞肺癌患者癌组织RAR-β基因甲基化及其临床意义。方法选择80例非小细胞肺癌患者,用甲基化特异性PCR(MSP)检测肺癌组织和癌旁正常组织RAR-β基因甲基化。结果肺癌组织RAR-β基因甲基化率(57.5%)高于癌旁组织甲基化率(17.5%),差异有统计学意义(P<0.01);临床分期0~Ⅰ期与Ⅱ~Ⅲ期相比、中央型与周围型相比,肺癌组织RAR-β基因甲基化检出率差异无统计学意义(P>0.05);不同病理分型肺癌组织RAR-β基因甲基化检测结果显示,鳞癌RAR-β基因甲基化检出率高于腺癌及其他,差异有统计学意义(P<0.05)。结论肺癌有关组织或样本的RAR-β基因甲基化,可能成为各种临床类型肺癌诊断的一个有效指标。
Objective To investigate the methylation of RAR-β gene in non-small cell lung cancer and its clinical significance. Methods Eighty patients with non-small cell lung cancer (NSCLC) were selected. Methylation-specific PCR (MSP) was used to detect methylation of RAR-β gene in lung cancer tissues and adjacent normal tissues. Results The methylation rate of RAR-β gene (57.5%) in lung cancer tissues was higher than that in paracancerous tissues (17.5%), the difference was statistically significant (P0.01). The clinical stage of stage 0 ~ Ⅰ and Ⅱ ~ Ⅲ Compared with peripheral type, there was no significant difference in methylation detection rate of RAR-βgene in lung cancer (P> 0.05). Methylation of RAR-βgene in different pathological types of lung cancer The results showed that the detection rate of methylation of RAR-βgene in squamous cell carcinoma was higher than that in adenocarcinoma and others (P <0.05). Conclusion The methylation of RAR-β gene in lung cancer tissues or samples may be a useful indicator for the diagnosis of various types of lung cancer.